Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile.

Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, Chowdhury FZ, Maswabi K, Ajibola G, Moyo S, Mohammed T, Ncube T, Makhema J, Jean-Philippe P, Yu XG, Powis KM, Lockman S, Kuritzkes DR, Shapiro R, Lichterfeld M.

Sci Transl Med. 2019 Nov 27;11(520). pii: eaax7350. doi: 10.1126/scitranslmed.aax7350.

PMID:
31776292
2.

Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.

Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A; IMPAACT P1078 TB APPRISE Study Team.

N Engl J Med. 2019 Oct 3;381(14):1333-1346. doi: 10.1056/NEJMoa1813060.

PMID:
31577875
3.

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.

Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C.

Lancet HIV. 2019 Aug;6(8):e552-e558. doi: 10.1016/S2352-3018(19)30147-X. Epub 2019 Jul 12. Review.

PMID:
31307946
4.

Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.

Bwakura Dangarembizi M, Samson P, Capparelli EV, Moore CB, Jean-Philippe P, Spector SA, Chakhtoura N, Benns A, Zimmer B, Purdue L, Jackson C, Wallis C, Libous JL, Chadwick EG; IMPAACT P1070 Study Team.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):473-480. doi: 10.1097/QAI.0000000000002061.

PMID:
31241542
5.

Eliminating perinatal HIV in the United States: mission possible?

Gnanashanmugam D, Rakhmanina N, Crawford KW, Nesheim S, Ruel T, Birkhead GS, Chakraborty R, Lawrence R, Jean-Philippe P, Jayashankar L, Hoover A, Statton A, DʼSouza P, Fitzgibbon J, Hazra R, Warren B, Smith S, Abrams EJ.

AIDS. 2019 Mar 1;33(3):377-385. doi: 10.1097/QAD.0000000000002080.

PMID:
30475262
6.

Validity of Neuropsychological Testing in Young African Children Affected by HIV.

Chernoff MC, Laughton B, Ratswana M, Familiar I, Fairlie L, Vhembo T, Kamthunzi P, Kabugho E, Joyce C, Zimmer B, Ariansen JL, Jean-Philippe P, Boivin MJ.

J Pediatr Infect Dis. 2018 Sep;13(3):185-201. doi: 10.1055/s-0038-1637020.

7.

Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana.

Ibrahim M, Maswabi K, Ajibola G, Moyo S, Hughes MD, Batlang O, Sakoi M, Auletta-Young C, Vaughan L, Lockman S, Jean-Philippe P, Yu X, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RL.

J Int AIDS Soc. 2018 May;21(5):e25111. doi: 10.1002/jia2.25111.

8.

Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy.

Hobbs CV, Gabriel EE, Kamthunzi P, Tegha G, Tauzie J, Li Y, Ilmet T, Artimovich E, Neal J, Hall T, Parikh S, Kirmse B, Jean-Philippe P, Chen J, Prescott WR, Palumbo P, Duffy PE, Borkowsky W, For The P S Study Team.

Am J Trop Med Hyg. 2018 Jan;98(1):67-70. doi: 10.4269/ajtmh.17-0462.

9.

HIV birth testing and linkage to care for HIV-infected infants.

Jean-Philippe P, Spiegel H, Gnanashanmugam D, Fitzgibbon J, DʼSouza P, Crawford KW, Jayashankar L, Bacon MC, Essajee SM, Aldrovandi GM, Cotton M, Abrams EJ.

AIDS. 2017 Aug 24;31(13):1797-1807. doi: 10.1097/QAD.0000000000001561.

PMID:
28590330
10.

Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.

Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e69-e74. doi: 10.1093/jpids/piw094.

11.

CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, Heckman B, Purdue L, Spector SA, Benns A, Borkowsky W, Loftis A, Hawkins E, Wallis C, Chadwick EG; IMPAACT P1070 team.

AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463.

12.

Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.

Zeldow B, Kim S, McSherry G, Cotton MF, Jean-Philippe P, Violari A, Bobat R, Nachman S, Mofenson LM, Madhi SA, Mitchell C.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):38-45. doi: 10.5588/ijtld.16.0149.

13.

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.

Hobbs CV, Gabriel EE, Kamthunzi P, Tegha G, Tauzie J, Petzold E, Barlow-Mosha L, Chi BH, Li Y, Ilmet T, Kirmse B, Neal J, Parikh S, Deygoo N, Jean Philippe P, Mofenson L, Prescott W, Chen J, Musoke P, Palumbo P, Duffy PE, Borkowsky W; P1068s Study Team.

PLoS One. 2016 Dec 9;11(12):e0165140. doi: 10.1371/journal.pone.0165140. eCollection 2016.

14.

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335.

15.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

16.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

17.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

18.

Understanding NIH clinical case definitions for pediatric intrathoracic TB by applying them to a clinical trial.

Beneri CA, Aaron L, Kim S, Jean-Philippe P, Madhi S, Violari A, Cotton MF, Mitchell C, Nachman S; P1041 team.

Int J Tuberc Lung Dis. 2016 Jan;20(1):93-100. doi: 10.5588/ijtld.14.0848.

19.

Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A.

Clin Infect Dis. 2016 Mar 15;62(6):761-769. doi: 10.1093/cid/civ991. Epub 2015 Dec 9.

20.

Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update.

Graham SM, Cuevas LE, Jean-Philippe P, Browning R, Casenghi M, Detjen AK, Gnanashanmugam D, Hesseling AC, Kampmann B, Mandalakas A, Marais BJ, Schito M, Spiegel HM, Starke JR, Worrell C, Zar HJ.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S179-87. doi: 10.1093/cid/civ581.

21.

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C.

Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. Review.

22.

Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.

Lange CM, Hué S, Violari A, Cotton M, Gibb D, Babiker A, Otwombe K, Panchia R, Dobbels E, Jean-Philippe P, McIntyre JA, Pillay D, Gupta RK.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):138-44. doi: 10.1097/QAI.0000000000000568.

23.

Longitudinal study on Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonization in HIV-infected and -uninfected infants vaccinated with pneumococcal conjugate vaccine.

Madhi SA, Izu A, Nunes MC, Violari A, Cotton MF, Jean-Philippe P, Klugman KP, von Gottberg A, van Niekerk N, Adrian PV; CIPRA 4 team.

Vaccine. 2015 May 28;33(23):2662-9. doi: 10.1016/j.vaccine.2015.04.024. Epub 2015 Apr 21.

24.

Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.

Lindsey JC, Hughes MD, Violari A, Eshleman SH, Abrams EJ, Bwakura-Dangarembizi M, Barlow-Mosha L, Kamthunzi P, Sambo PM, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Zimmer B, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P; P1060 Study Team.

Pediatr Infect Dis J. 2014 Aug;33(8):846-54. doi: 10.1097/INF.0000000000000337.

25.

Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.

Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, Josipovic D, Liberty A, Lazarus E, Innes S, van Rensburg AJ, Pelser W, Truter H, Madhi SA, Handelsman E, Jean-Philippe P, McIntyre JA, Gibb DM, Babiker AG; CHER Study Team.

Lancet. 2013 Nov 9;382(9904):1555-63. doi: 10.1016/S0140-6736(13)61409-9.

26.

Ethical tradeoffs in trial design: case study of an HPV vaccine trial in HIV-infected adolescent girls in lower income settings.

Lindsey JC, Shah SK, Siberry GK, Jean-Philippe P, Levin MJ.

Dev World Bioeth. 2013 Aug;13(2):95-104. doi: 10.1111/dewb.12028. Epub 2013 May 31.

27.

Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth.

Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL, Jean-Philippe P, Fenton T, Siberry GK; IMPAACT P1065 Protocol Team.

Clin Vaccine Immunol. 2013 Jun;20(6):900-6. doi: 10.1128/CVI.00042-13. Epub 2013 Apr 17.

28.

Reply to Holm et al.

Graham SM, Casenghi M, Jean-Philippe P, Hatherill M, Hesseling AC, Nachman S, Starke JR, Swaminathan S, Cuevas LE.

J Infect Dis. 2013 Mar 1;207(5):871-2. doi: 10.1093/infdis/jis769. Epub 2012 Dec 13. No abstract available.

PMID:
23242541
29.

Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa.

Beneri CA, Zeldow B, Nachman S, Van der Linde M, Pillay E, Dittmer S, Kim S, Jean-Philippe P, Coetzee J, Bobat R, Hawkins E, Violari A; P1041 Team.

Int J Tuberc Lung Dis. 2013 Jan;17(1):32-8. doi: 10.5588/ijtld.12.0282.

30.

Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.

Madhi SA, Izu A, Violari A, Cotton MF, Panchia R, Dobbels E, Sewraj P, van Niekerk N, Jean-Philippe P, Adrian PV; CIPRA-4 team.

Vaccine. 2013 Jan 21;31(5):777-83. doi: 10.1016/j.vaccine.2012.11.076. Epub 2012 Dec 8.

31.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, Chi BH, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P.

N Engl J Med. 2012 Jun 21;366(25):2380-9. doi: 10.1056/NEJMoa1113249.

32.

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team.

J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.

33.

Early antiretroviral therapy improves neurodevelopmental outcomes in infants.

Laughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, van Rensburg AJ, Violari A, Babiker AG, Madhi SA, Jean-Philippe P, Gibb DM, Cotton MF.

AIDS. 2012 Aug 24;26(13):1685-90.

34.

Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel.

Cuevas LE, Browning R, Bossuyt P, Casenghi M, Cotton MF, Cruz AT, Dodd LE, Drobniewski F, Gale M, Graham SM, Grzemska M, Heinrich N, Hesseling AC, Huebner R, Jean-Philippe P, Kabra SK, Kampmann B, Lewinsohn D, Li M, Lienhardt C, Mandalakas AM, Marais BJ, Menzies HJ, Montepiedra G, Mwansambo C, Oberhelman R, Palumbo P, Russek-Cohen E, Shapiro DE, Smith B, Soto-Castellares G, Starke JR, Swaminathan S, Wingfield C, Worrell C.

J Infect Dis. 2012 May 15;205 Suppl 2:S209-15. doi: 10.1093/infdis/jir879. Epub 2012 Apr 3.

35.

Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesseling AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C.

J Infect Dis. 2012 May 15;205 Suppl 2:S199-208. doi: 10.1093/infdis/jis008. Epub 2012 Mar 22.

36.

Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs.

Zumla A, Atun R, Maeurer M, Kim PS, Jean-Philippe P, Hafner R, Schito M.

J Infect Dis. 2012 May 15;205 Suppl 2:S141-6. doi: 10.1093/infdis/jir880. Epub 2012 Mar 22. No abstract available.

37.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

38.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team.

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

39.

Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Madhi SA, Violari A, Klugman KP, Lin G, McIntyre JA, von Gottberg A, Jean-Philippe P, Cotton MF, Adrian P; CIPRA 4 team.

Vaccine. 2011 Sep 16;29(40):6994-7001. doi: 10.1016/j.vaccine.2011.07.035. Epub 2011 Jul 23.

40.

Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.

Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C; P1041 Study Team.

N Engl J Med. 2011 Jul 7;365(1):21-31. doi: 10.1056/NEJMoa1011214.

41.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

42.

Antiretroviral treatment for children with peripartum nevirapine exposure.

Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A.

N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.

43.

Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants.

Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, Nachman S, Käyhty H, Klugman KP, Violari A; Comprehensive International Program of Research on AIDS 4 Study Team.

J Infect Dis. 2010 Aug 15;202(3):355-61. doi: 10.1086/653704.

44.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

45.

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D.

Pediatr Infect Dis J. 2009 Feb;28(2):159-61. doi: 10.1097/INF.0b013e3181861d8b.

46.

Early antiretroviral therapy and mortality among HIV-infected infants.

Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team.

N Engl J Med. 2008 Nov 20;359(21):2233-44. doi: 10.1056/NEJMoa0800971.

47.

Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.

Rigaud M, Borkowsky W, Muresan P, Weinberg A, Larussa P, Fenton T, Read JS, Jean-Philippe P, Fergusson E, Zimmer B, Smith D, Kraimer J; Pediatrics AIDS Clinical Trials Group P1006 Team.

J Infect Dis. 2008 Oct 15;198(8):1123-30. doi: 10.1086/592050.

48.

Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction.

Jean-Philippe P, Freedman A, Chang MW, Steinberg SP, Gershon AA, LaRussa PS, Borkowsky W.

Pediatrics. 2007 Nov;120(5):e1345-9. Review.

PMID:
17974726
49.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
50.

Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline.

Nikolic-Djokic D, Essajee S, Rigaud M, Kaul A, Chandwani S, Hoover W, Lawrence R, Pollack H, Sitnitskaya Y, Hagmann S, Jean-Philippe P, Chen SH, Radding J, Krasinski K, Borkowsky W.

J Infect Dis. 2002 Feb 1;185(3):290-8. Epub 2002 Jan 8.

PMID:
11807710

Supplemental Content

Loading ...
Support Center